From CO2 to Er:YAG: A Comprehensive Review of Laser Treatments for Rhinophyma.

IF 1.5 4区 医学 Q3 DERMATOLOGY Journal of Drugs in Dermatology Pub Date : 2024-11-01 DOI:10.36849/JDD.8199
Payvand Kamrani, Monica Boen, Sabrina G Fabi, Mitchel P Goldman
{"title":"From CO2 to Er:YAG: A Comprehensive Review of Laser Treatments for Rhinophyma.","authors":"Payvand Kamrani, Monica Boen, Sabrina G Fabi, Mitchel P Goldman","doi":"10.36849/JDD.8199","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Rhinophyma, a benign condition resulting in nasal sebaceous tissue hypertrophy, predominantly affects Caucasian males. There are numerous surgical and medical treatments for rhinophyma with varying degrees of success. This review aims to provide a comprehensive overview of ablative therapies, highlighting our preferred treatment approach.</p><p><strong>Methods: </strong>This review analyzes the evidence behind ablative lasers in treating rhinophyma, with a focus on the 10600 nm carbon dioxide (CO2) and 2940 nm erbium: yttrium-aluminum-garnet (Er:YAG).</p><p><strong>Results: </strong>Both CO2 and Er:YAG have demonstrated efficacy in treating rhinophyma. CO2 laser ablation results in a higher incidence of scarring and hypopigmentation. Er:YAG has high water absorption, which results in less thermal damage, allowing for quicker healing and fewer complications.</p><p><strong>Conclusion: </strong>Management of rhinophyma can remain challenging; however, ablative lasers are an effective treatment. Both laser types have promising outcomes, each with different advantages and complications. In particular, Er:YAG presents fewer complications compared to CO2 lasers. J Drugs Dermatol. 2024;23(11):932-936. doi:10.36849/JDD.8199.</p>","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.8199","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Rhinophyma, a benign condition resulting in nasal sebaceous tissue hypertrophy, predominantly affects Caucasian males. There are numerous surgical and medical treatments for rhinophyma with varying degrees of success. This review aims to provide a comprehensive overview of ablative therapies, highlighting our preferred treatment approach.

Methods: This review analyzes the evidence behind ablative lasers in treating rhinophyma, with a focus on the 10600 nm carbon dioxide (CO2) and 2940 nm erbium: yttrium-aluminum-garnet (Er:YAG).

Results: Both CO2 and Er:YAG have demonstrated efficacy in treating rhinophyma. CO2 laser ablation results in a higher incidence of scarring and hypopigmentation. Er:YAG has high water absorption, which results in less thermal damage, allowing for quicker healing and fewer complications.

Conclusion: Management of rhinophyma can remain challenging; however, ablative lasers are an effective treatment. Both laser types have promising outcomes, each with different advantages and complications. In particular, Er:YAG presents fewer complications compared to CO2 lasers. J Drugs Dermatol. 2024;23(11):932-936. doi:10.36849/JDD.8199.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
从 CO2 到 Er:YAG:鼻叶斑激光疗法综合评述。
背景:鼻赘是一种导致鼻腔皮脂腺组织肥大的良性疾病,主要影响白种男性。目前有许多手术和药物治疗鼻赘的方法,但成功率各不相同。本综述旨在全面概述消融疗法,重点介绍我们首选的治疗方法:本综述分析了烧蚀激光治疗鼻赘的证据,重点是 10600 纳米二氧化碳(CO2)和 2940 纳米铒:钇铝石榴石(Er:YAG):结果:二氧化碳激光和 Er:YAG 激光在治疗鼻息肉方面都有显著疗效。CO2 激光消融会导致较高的瘢痕和色素沉着发生率。Er:YAG 具有较高的吸水性,热损伤较小,因此愈合更快,并发症更少:结论:鼻大疱的治疗仍具有挑战性,但烧蚀激光是一种有效的治疗方法。两种激光类型都有良好的疗效,但各有不同的优点和并发症。尤其是 Er:YAG 激光与 CO2 激光相比,并发症更少。J Drugs Dermatol.2024;23(11):932-936. doi:10.36849/JDD.8199.
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
2.20
自引率
13.30%
发文量
289
审稿时长
3-6 weeks
期刊介绍: The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.
期刊最新文献
Efficacy of Topical Finasteride 0.25% With Minoxidil 5% Versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia. From CO2 to Er:YAG: A Comprehensive Review of Laser Treatments for Rhinophyma. GLP-1 Receptor Agonists for the Dermatologist: Uses and Considerations. INDIVIDUAL ARTICLE: All for One and One for All: The Three Musketeers of Topical Acne Treatment and the Current Landscape. A Review of Energy-Based Device Interventions to Treat Keloid Scars.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1